Nanotheranostics with Radionuclides for Cancer Diagnosis and Therapy
Source abstract
Abstract
Abstract Anti‐tumor theranostic radionuclide nanosystems have gained significant attention as an emerging therapeutic strategy. This review systematically elucidates the concept and recent advances of anti‐tumor nanotheranostic systems with radionuclides, with a focus on the design of nanocarriers, precise selection of radionuclides, and their advantages and limitations in clinical translation. This review also explores the integration of radionuclide imaging with various treatment modalities, including photodynamic therapy, photothermal therapy, sonodynamic therapy, and immunotherapy. Furthermore, the combination of radionuclide therapy with fluorescence imaging and magnetic resonance imaging technologies, which broadens the application of nanotheranostics, is discussed. Finally, the review outlooks the future development of anti‐tumor nanotheranostics with radionuclides and proposes a key research focus.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Radiopharmaceutical Chemistry and Applications · Nanoplatforms for cancer theranostics · Medical Imaging Techniques and Applications
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Beijing National Laboratory for Molecular Sciences Laboratory of Polymer Physics and Chemistry Institute of Chemistry Chinese Academy of Sciences Beijing 100190 P. R. China
University of Chinese Academy of Sciences Beijing 100049 P. R. China
Department of Chemical and Biomolecular Engineering University of California Los Angeles CA 90066 USA
Department of Nuclear Medicine Peking University People's Hospital Beijing 100044 P. R. China
Funding
National Natural Science Foundation of China
References (100+)
Show source-provided references
1. 10.1158/0008-5472.CAN-07-661110.1158/0008-5472.CAN-07-6611 ↗
2. 10.1016/S0140-6736(21)00233-610.1016/S0140-6736(21)00233-6 ↗
3. 10.1002/advs.20200358410.1002/advs.202003584 ↗
4. 10.1021/acsnano.3c0601910.1021/acsnano.3c06019 ↗
5. 10.1016/j.ccr.2023.21553010.1016/j.ccr.2023.215530 ↗
6. 10.1007/s40820-019-0266-010.1007/s40820-019-0266-0 ↗
7. 10.1016/j.bioactmat.2024.03.01410.1016/j.bioactmat.2024.03.014 ↗
8. 10.7150/thno.2499710.7150/thno.24997 ↗
9. 10.1016/j.ymthe.2018.02.01910.1016/j.ymthe.2018.02.019 ↗
10. Tao D. · Adv. Drug. Deliv. Rev. · 2018 · 28
11. 10.1002/adhm.20200080210.1002/adhm.202000802 ↗
12. 10.1021/acsnano.0c0432410.1021/acsnano.0c04324 ↗
13. 10.1002/adma.20230004810.1002/adma.202300048 ↗
14. 10.1021/acs.nanolett.9b0526710.1021/acs.nanolett.9b05267 ↗
15. 10.1186/s12951-021-00802-x10.1186/s12951-021-00802-x ↗
16. 10.1016/j.jconrel.2024.04.03210.1016/j.jconrel.2024.04.032 ↗
17. 10.1002/adma.20210683810.1002/adma.202106838 ↗
18. 10.1002/smll.20230032710.1002/smll.202300327 ↗
19. 10.1126/scitranslmed.add271210.1126/scitranslmed.add2712 ↗
20. 10.1021/jacs.3c1270610.1021/jacs.3c12706 ↗
21. 10.1002/adhm.20230094410.1002/adhm.202300944 ↗
22. 10.7150/thno.8748910.7150/thno.87489 ↗
23. 10.1016/j.jcis.2023.03.11110.1016/j.jcis.2023.03.111 ↗
24. 10.1016/j.jacc.2008.03.03610.1016/j.jacc.2008.03.036 ↗
25. 10.1007/s00134-017-4702-710.1007/s00134-017-4702-7 ↗
26. 10.1118/1.293621710.1118/1.2936217 ↗
27. 10.4103/amhs.amhs_97_1710.4103/amhs.amhs_97_17 ↗
28. 10.1016/S0735-1097(96)00435-410.1016/S0735-1097(96)00435-4 ↗
29. 10.1109/TNS.1980.433098610.1109/TNS.1980.4330986 ↗
30. 10.1186/s12951-019-0524-910.1186/s12951-019-0524-9 ↗
31. 10.1038/s41392-023-01366-y10.1038/s41392-023-01366-y ↗
32. 10.3390/diagnostics1413143110.3390/diagnostics14131431 ↗
33. 10.1088/1361-6560/aadc8810.1088/1361-6560/aadc88 ↗
34. 10.1016/j.jsps.2022.12.01310.1016/j.jsps.2022.12.013 ↗
35. 10.1109/TNS.1975.432766010.1109/TNS.1975.4327660 ↗
36. 10.1016/j.ejmp.2024.10335710.1016/j.ejmp.2024.103357 ↗
37. 10.1148/radiology.159.2.348580310.1148/radiology.159.2.3485803 ↗
38. 10.1007/s00259-005-1760-910.1007/s00259-005-1760-9 ↗
39. 10.1016/j.radcr.2018.07.02110.1016/j.radcr.2018.07.021 ↗
40. 10.1016/S0001-2998(98)80027-510.1016/S0001-2998(98)80027-5 ↗
41. 10.1039/B922628C10.1039/B922628C ↗
42. 10.1007/s00259-022-05824-710.1007/s00259-022-05824-7 ↗
43. 10.1038/s41467-023-36377-410.1038/s41467-023-36377-4 ↗
44. 10.1039/C6CS00492J10.1039/C6CS00492J ↗
45. 10.1007/s12022-008-9044-010.1007/s12022-008-9044-0 ↗
46. 10.1016/S1474-4422(20)30314-810.1016/S1474-4422(20)30314-8 ↗
47. 10.1016/S1474-4422(16)30140-510.1016/S1474-4422(16)30140-5 ↗
48. 10.1021/acs.chemrev.1c0076710.1021/acs.chemrev.1c00767 ↗
49. 10.3390/ijms2309502310.3390/ijms23095023 ↗
50. 10.1007/BF0018413010.1007/BF00184130 ↗
51. 10.1016/j.nucmedbio.2007.06.01310.1016/j.nucmedbio.2007.06.013 ↗
52. Caobelli F. · Eur. Heart. J. · 2017 · 38 · 436
53. 10.7150/thno.2439510.7150/thno.24395 ↗
54. 10.1002/anie.20130280010.1002/anie.201302800 ↗
55. 10.1007/s42452-020-03524-110.1007/s42452-020-03524-1 ↗
56. 10.1016/j.nucmedbio.2020.05.00510.1016/j.nucmedbio.2020.05.005 ↗
57. 10.3400/avd.di.10.1000610.3400/avd.di.10.10006 ↗
58. 10.3390/ijms1805107910.3390/ijms18051079 ↗
59. 10.1016/j.biomaterials.2014.04.09810.1016/j.biomaterials.2014.04.098 ↗
60. 10.1016/j.ijpharm.2021.12088410.1016/j.ijpharm.2021.120884 ↗
61. 10.2967/jnumed.111.10413310.2967/jnumed.111.104133 ↗
62. 10.1002/anie.20180550110.1002/anie.201805501 ↗
63. 10.1016/j.drudis.2014.09.02710.1016/j.drudis.2014.09.027 ↗
64. 10.1002/anie.20080022210.1002/anie.200800222 ↗
65. 10.1038/s41596-020-00407-y10.1038/s41596-020-00407-y ↗
66. 10.1158/1078-0432.CCR-13-266610.1158/1078-0432.CCR-13-2666 ↗
67. 10.1186/s13550-015-0095-110.1186/s13550-015-0095-1 ↗
68. 10.1007/s11547-014-0446-410.1007/s11547-014-0446-4 ↗
69. 10.1016/j.neuroimage.2005.03.01210.1016/j.neuroimage.2005.03.012 ↗
70. 10.1001/jamanetworkopen.2024.2343510.1001/jamanetworkopen.2024.23435 ↗
71. 10.1634/theoncologist.2019-009610.1634/theoncologist.2019-0096 ↗
72. 10.1007/s00259-023-06488-710.1007/s00259-023-06488-7 ↗
73. 10.2967/jnumed.107.04350510.2967/jnumed.107.043505 ↗
74. 10.2967/jnumed.113.12078210.2967/jnumed.113.120782 ↗
75. 10.1177/028418511349667910.1177/0284185113496679 ↗
76. 10.2967/jnumed.117.19119710.2967/jnumed.117.191197 ↗
77. 10.3390/ijms2112430910.3390/ijms21124309 ↗
78. 10.1002/advs.20200187910.1002/advs.202001879 ↗
79. 10.1038/s41591-018-0255-810.1038/s41591-018-0255-8 ↗
80. 10.1039/C9CS00840C10.1039/C9CS00840C ↗
81. 10.1016/S0140-6736(99)06002-X10.1016/S0140-6736(99)06002-X ↗
82. 10.1016/S1470-2045(21)00657-410.1016/S1470-2045(21)00657-4 ↗
83. 10.1038/s41586-024-07461-610.1038/s41586-024-07461-6 ↗
84. 10.3322/caac.2157810.3322/caac.21578 ↗
85. 10.1016/j.addr.2022.11453810.1016/j.addr.2022.114538 ↗
86. 10.1038/sj.cdd.440104710.1038/sj.cdd.4401047 ↗
87. 10.1016/S1470-2045(24)00030-510.1016/S1470-2045(24)00030-5 ↗
88. 10.1038/s41573-020-0073-910.1038/s41573-020-0073-9 ↗
89. 10.7150/thno.10192210.7150/thno.101922 ↗
90. 10.7150/thno.9674310.7150/thno.96743 ↗
91. 10.7150/thno.2221710.7150/thno.22217 ↗
92. 10.1021/acs.accounts.1c0032710.1021/acs.accounts.1c00327 ↗
93. 10.1186/s13046-021-02056-910.1186/s13046-021-02056-9 ↗
94. 10.1039/C5CS00712G10.1039/C5CS00712G ↗
95. 10.1016/j.colsurfb.2023.11317410.1016/j.colsurfb.2023.113174 ↗
96. 10.1038/s41585-019-0251-x10.1038/s41585-019-0251-x ↗
97. 10.1186/s13046-023-02636-x10.1186/s13046-023-02636-x ↗
98. 10.1200/JCO.2021.39.15_suppl.411710.1200/JCO.2021.39.15_suppl.4117 ↗
99. 10.1016/j.addr.2015.12.00310.1016/j.addr.2015.12.003 ↗
100. 10.7150/thno.3117910.7150/thno.31179 ↗